During TIDES 2018 discuss oligonucleotide development challenges with our experts, May 7- 10, 2018, Boston, USA
Accelerating oligonucleotide products from early discovery to late-stage development & commercialization is not without challenges.
With a growing global development pipeline of oligonucleotide therapeutics to treat a variety of disease targets, overcoming the challenges of innovation, regulatory authorization, production and the inherent complexity of oligos is critical to success.
During TIDES 2018, the Intertek team will be available to discuss your outsourcing requirements to address the critical stages of chemistry, manufacturing and controls (CMC), marketing authorization and GMP manufacturing. Our experts in oligonucleotide analysis and bioanalysis, will be on hand to discuss our regulatory-driven, phase-appropriate characterization and biophysical analysis in support of CMC programs which include confirmation of the oligonucleotide identity, assay, and identification / determination of impurities and degradation products.
TIDES INTERTEK SPOTLIGHT PRESENTATION
Thursday, 10 May 2018, 12:20pm - 12:50pm
Title: Analytical Challenges in the Characterisation of Therapeutic Oligonucleotides
Speaker: Jordi Trafach, Characterisation Manager, Intertek Pharmaceutical Services
Email our OLIGOS TEAM to register your interest in receiving the slides (after the event)
Our specialists in GMP and CMC laboratory services, pharmaceutical analysis, quality control analysis, elemental impurities, extractables and leachables, stability programs, inhalation drug development, method development and method validation will be available to review your challenges and discuss and how our unrivalled expertise can help you to accelerate the development timelines.
Learn more about TIDES 2018
TIDES 2018 is an opportunity to discuss best practices and learn more about important industry developments across the entire spectrum of oligonucleotide and peptide therapeutics. During the conference the topics of R&D strategies, oligonucleotide manufacturing and scale up, nonclinical, preclinical and clinical updates for oligonucleotides, mRNA therapeutics, CMC and analytical method development strategies for oligonucleotides will be discussed.
Need help or have a question?